Use of quinoline-3-carboxamide compounds

• US 5,728,713 A
• Filed: 10/29/1996
• Issued: 03/17/1998
• Est. Priority Date: 03/10/1994
• Status: Expired due to Fees

• Current Assignee: Pharmacia & Upjohn AB (Pharmacia Corp.)
• Original Assignee: Pharmacia & Upjohn LLC (Pfizer Inc.)
• Inventors: Nilsson, Bo, Gjorstrup, Per, Svedberg, Agneta
• Primary Examiner(s): Cintins, Marianne M.
• Assistant Examiner(s): Jones, Dwayne C.
• Application Number:
  US08/704,588
• Time in Patent Office: 504 Days
• Field of Search: 514/312, 514/311
• US Class Current: 514/312
• CPC Class Codes: A61K 31/47 Quinolines; Isoquinolines
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: C07D 215/56 with oxygen atoms in position 4

Abstract

Method of treating inflammatory bowel disease with a quinoline-3-carboxamide compound comprising ##STR1## structure (I), optionally with substituents for the hydrogen atoms shown: (H^1-9), or a pharmaceutically acceptable salt of said compound where: (a) - - - represents that there are two conjugated double bonds between the atoms comprised by the dashed line; (b) X₁ and X₂ are separately selected from an oxygen atom or an NH⁹ group, said X₁ and X₂ being bound by a single bond to the ring when attached to H⁷ or H⁸ and by a double bond when not bound to H⁷ or H⁸ ; (c) H^1-9 are hydrogens with the provision that H⁹ is only present when at least one of X₁ and X₂ is the NH⁹ group; (d) H⁷ and H⁸ are hydrogens that are attached to different atoms selected among X₁, X₂ and the nitrogen atom (N) in the quinoline ring, for the manufacture of a composition intended for treating inflammatory bowel disease or conditions associated with this disease. Also described are methods for treating inflammatory bowel disease or conditions associated with this disease in which methods the above compounds are administered to a living body. Particularly preferred compounds are N-phenyl-N-methyl-1,2-dihydro-4-hydroxy-1-methyl-2-oxo-quinoline-3-carboxamide or a salt thereof.

Claims

1. A method for treating a patient suffering from, or at risk for acquiring, inflammatory bowel disease, comprising administering to the patient an effective therapeutic dose of N-phenyl-N-methyl-1,2-dihydro-4-hydroxy-1-methyl-2-oxo-quinoline-3-carboxamide or tautomers thereof, or a pharmaceutically acceptable salt thereof.

2. The method of claim 1, wherein the compound is administered orally.

3. The method of claim 1, whereby said compound is administered by injection.

4. The method of claim 1, whereby said compound is administered parenterally.

5. The method of claim 1, 2, 3, or 4, wherein the effective amount is from about 0.01 to about 10 mg/kg body weight and the amount is administered from once daily to once every two weeks.

6. The method of claim 5, wherein the effective amount is from about 0.05 to about 1 mg/kg body weight.